Skip to content

A Type I Hybrid Effectiveness-Implementation Trial of MIO

A Type I Hybrid Effectiveness-Implementation Trial of Mothering From the Inside Out (MIO)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07168642
Enrollment
200
Registered
2025-09-11
Start date
2025-12-23
Completion date
2029-07-31
Last updated
2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Use Disorder

Keywords

substance use disorder, parenting, parenting intervention, Mothering from the Inside Out, MIO, SUD treatment

Brief summary

Mothers with substance use disorders face unprecedented stress in their roles as parents working to care for their children while maintaining healthy recovery. Mothering from the Inside Out (MIO) is the first attachment-based parenting intervention designed specifically for mothers in recovery from substance use disorders that has been shown to have benefit for both mother and child in multiple randomized controlled trials. This project will: (a) test the effectiveness of MIO among women in outpatient treatment under 'real-world' conditions, (b) evaluate implementation in different settings, and (c) assess key implementation factors to support optimal uptake and treatment in future dissemination studies; closing an important science-to-service gap for an underserved population in an effort to support maternal and child health simultaneously.

Detailed description

Pregnancy and parenting can be life-changing motivators for women with substance use disorders (SUDs) to seek treatment. However, the rate of relapse and overdose for women with SUDs increases sharply after the birth of a child, such that mental health and drug-related deaths are a leading preventable cause of postpartum mortality. Heightened parental stress and lack of adequate parenting supports increase the risk of drug overdose. Mothers with SUDs are also more likely to exhibit maladaptive parenting behaviors associated with long-term developmental, behavioral, and emotional problems in their offspring. Despite the well-established interaction between parenting and SUDs during a critical period, SUD treatment does not systematically include targeted parenting support for mothers in recovery and their young children. Mothering from the Inside Out (MIO) is an evidence-based, individual parenting intervention designed as an adjunct to outpatient SUD treatment that targets parental reflective functioning, i.e., the capacity to understand behavior, for oneself and one's child, in terms of underlying mental states. MIO has proven bigenerational efficacy in two randomized trials when delivered by researchers under tightly controlled research conditions. Mothers assigned to MIO demonstrated significantly improved parenting capacities and reduced substance use compared with those assigned to parental education. Although MIO was efficacious when delivered by expert clinicians in highly organized research settings, there are challenges to exporting any evidence-based practice to dynamic real-world environments creating a science-to-service gap. As a first step in addressing these challenges, we successfully trained SUD and mental health counselors to deliver MIO with fidelity in community clinics. Yet, in the only community-based efficacy trial where MIO was delivered by SUD treatment counselors, MIO offered some advantages over parental education with respect to reduction in substance use and depressive symptoms, but MIO did not yield the same magnitude of improvement in parenting as it did in the first two randomized controlled trials. Community-academic partnerships and governmental funding support in Massachusetts have since allowed our multi-disciplinary team to identify barriers to implementation and develop a practice-informed implementation strategy to mitigate these barriers. We are now poised to simultaneously test the clinical effectiveness of MIO and the utility of our implementation strategy in community-based clinical settings. With guidance from our two community partners, we are proposing a Hybrid Type II research project to test the effectiveness and implementation of MIO as an adjunct to treatment as usual (TAU). SUD counselors (n=16) and mothers enrolled in outpatient SUD treatment (n=200) caring for children ≤5 years of age will be recruited from four SUD treatment clinics operated by two community agencies in Massachusetts. These sites were selected by our community partners based on their generalizability and engagement with parents with SUDs. Mothers will be randomized in a 2:1 fashion to the receipt of either MIO+TAU or TAU to allow for dual examination of the implementation process as well as the MIO mechanism of change. Guided by established frameworks and our implementation conceptual model, we will use a mixed-methods approach to evaluate the relationship between key contextual determinants of MIO implementation. Our specific aims include the following: Aim 1. Compare the effectiveness of MIO+TAU versus TAU alone. Hypotheses: Compared with mothers receiving TAU, mothers randomized to MIO+TAU will demonstrate a greater increase in parental reflective functioning and greater decrease in parenting stress (primary outcomes) at the end of treatment. They will also demonstrate greater improvement in quality of mother-child interactions and greater decreases in drug use and psychiatric distress (secondary outcomes) at 3-month follow-up. Aim 2. Assess differences in agency- and clinic-level implementation processes with respect to a) completion of implementation activities, b) tailoring strategies, and c) implementation outcomes. Hypothesis: Facilitated completion of pre-implementation activities at the agency- and clinic-level will predict greater reach, adoption, feasibility, and fidelity of MIO across four clinical units. Aim 3. Identify key contextual determinants associated with successful MIO implementation and effectiveness, supported by integration of qualitative and quantitative data to guide large-scale dissemination. Hypothesis 3a: Primary implementation outcomes (MIO fidelity and feasibility) will be determined by organizational climate, characteristics of individual counselors, and execution of the implementation process integrity. Hypothesis 3b: The association between primary implementation outcomes (MIO fidelity and feasibility) and secondary effectiveness outcomes (quality of mother-child interactions, maternal drug use, and psychiatric distress) will be mediated by parental reflective functioning and parenting stress (primary effectiveness outcomes). Moving evidence-based practices into routine care settings is a public health and NIDA priority. When completed, this project will allow us to address the critical gap between research and practice by providing data to support large-scale implementation of MIO in community settings.

Interventions

BEHAVIORALMothering from the Inside Out

Mothering from the Inside Out (MIO) is an evidence-based individual psychotherapy designed to help caregivers in recovery build stronger relationships with their children. In MIO, caregivers are helped to build their ability to reflect on their own mental states and how they arose. Often, we find that the thoughts and feelings that drive caregiving behavior are actually triggered by early experiences of being cared for. MIO thus aims to provide a safe, therapeutic space where caregivers' internal experiences are taken seriously and clinicians are genuinely interested, curious, and collaborative. MIO also involves helping caregivers to reflect on the possible mental states underlying their children's behavior. We find that by providing some information about child development through an attachment lens, this can help parents see through their children's eyes and feel less stressed.

Sponsors

Baystate Medical Center
Lead SponsorOTHER
Behavioral Health Network
CollaboratorUNKNOWN
Spectrum Health Systems
CollaboratorUNKNOWN

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Client Subjects Inclusion Criteria: * Identifies as a woman * English-speaking * Age 18 years or older * Enrolled in outpatient substance use treatment for a substance use disorder (by DSMV criteria) at one of the four target clinics operated by participating agencies * Caring for at least one child between 0 and 60 months of age (either as guardian or working towards reunification with regular contact)

Exclusion criteria

* Have severe mental health problems (e.g., actively suicidal, homicidal, psychosis) * Severely cognitively impaired * Have psychiatric or substance-related symptoms requiring inpatient hospitalization or ambulatory detoxification * Unable to speak English * Have a potential target child who has a severe medical condition that limits their ability to interact with their mother (such as paralysis or severe weakness) Children Subjects Inclusion Criteria: * Age 5 years or younger * Are in their biological mother's custody OR are in custody of family with the goal of reunification with their biological mother and have permission from the child's legal guardian to participate in this study

Design outcomes

Primary

MeasureTime frameDescription
Parental Reflective FunctioningBaseline, post treatment (week 21)The Parent Development Interview (PDI) is a semi-structured clinical interview with 19 questions intended to examine parents' representations of their children, themselves as parents, and their relationships with their children. The PDI is coded using an 11-point reflective functioning rating scale (-1 to 9) where higher score indicates higher reflective capacity.
Parenting StressBaseline, during treatment (week 13), post treatment (week 21), follow-up (week 33)The Parenting Stress Index-Short Form (PSI-SF) is a 36-item questionnaire used to assess parenting stress on a 5-point Likert scale. It's a briefer version of the full Parenting Stress Index, designed to be more efficient for clinical and research settings. The PSI-SF measures three key areas: Parental Distress, Parent-Child Dysfunctional Interaction, and Difficult Child, which together contribute to an overall measure of parenting stress, minimum score 36 and maximum 180. Scores at or above the 85th percentile on the Total Stress scale are considered to be borderline clinically significant.

Secondary

MeasureTime frameDescription
Quality of mother-child interactionBaseline, follow-up (week 33)The Coding Interactive Behavior (CIB) is a global rating system for analyzing social interactions between two or more partners, in this case, mother and child (videotaped play session with recommended age-appropriate toys). The CIB consists of 33 items (18 relating to the parent, 8 to the child, 5 to the dyad, and 2 focusing on the lead-lag of the interaction) that are rated from 1 (minimal level of behavior) to 5 (maximum level of behavior). Minimum possible score is 33, maximum is 165. A higher score indicates a more positive and adaptive interactive behavior between parent and child.
Substance UseBaseline, monthly during weeks 1-21, post treatment (week 21)Toxicology testing is a method to detect the presence of drugs or other chemicals in a person's urine. This testing is already being completed as a normal procedure by the SUD treatment agencies, and the results on study participants only are shared with the study team on a monthly basis.
AnxietyBaseline, during treatment (week 13), post treatment (week 21)The General Anxiety Disorder-7 (GAD-7) is a 7-item screening tool used to assess the severity of generalized anxiety disorder. Each item is rated on a 0-3 scale, with higher scores indicating greater anxiety. Minimum score 0, maximum score 21.
DepressionBaseline, during treatment (week 13), post treatment (week 21)The Patient Health Questionnaire-9 (PHQ-9) is a self-administered tool used to screen for and assess the severity of depression. It consists of nine questions, each scored from 0 (not at all) to 3 (nearly every day), with a total possible score ranging from 0 to 27. Higher scores indicate more severe depression, and scores are categorized into ranges to suggest severity levels: minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe (20-27).
MIO FidelityIntervention period weeks 4-21Mothering from the Inside Out - Treatment Fidelity Scales - Revised (MIO-TFS-R) is used to code MIO sessions in frequency and competence across 10 competencies with scores for each competency ranging from 0 to 3. Four of these competencies are MIO-specific, with higher scores on MIO items indicating greater fidelity to the MIO model. For both frequency and competence, the minimum possible overall score is 10 the maximum possible overall score is 30. The minimum score for MIO-specific items is 4, and the maximum is 12.
MIO FeasibilityAfter each MIO treatment (week 21 of each mother's participation period)Number of MIO sessions completed in a 16-week period
Organizational CultureYears 1 & 5The Organizational Climate Measuring Tool (OCMT) is a standardized scale measuring agency culture. It uses a Likert-type scale of 10 points (1 = maximum disagreement; 10 = maximum agreement) to examine motivation, leadership, and management philosophy.
Organizational AttitudesYears 1 & 5The Evidence-Based Practice Questionnaire (EBPQ) measures individuals' attitudes towards, knowledge of, and implementation of evidence-based practice, and the extent to which barriers may prevent greater uptake of evidence-based practice. The questionnaire contains 24 items scored on a seven-point Likert scale, with lower scores corresponding to poor attitude. There are 3 subscales: practice of evidence-based practice (6 items), attitude towards evidence-based practice (4 items), and knowledge/skills associated with evidence-based practice (14 items).

Countries

United States

Contacts

CONTACTElizabeth Peacock-Chambers, MD, MSc
elizabeth.peacock-chambers@baystatehealth.org413-794-8301
CONTACTBriana L Jurkowski, BS
briana.jurkowski@baystatehealth.org413-794-8833

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 9, 2026